Philip Morris takes $500M impairment on Canadian unit, trims 2026 EPS forecast for FX

Filed June 2, 2026 · Period ending June 2, 2026 · ~2 min read

Key Changes

• high

  PM will record a $500 million non-cash impairment charge (33 cents per share) on its Canadian affiliate RBH in Q2 2026, following updated five-year projections submitted to the court-appointed Plan Administrator. Remaining carrying value will be under $100 million.

  Exhibit 99.1 verify on EDGAR →
• high

  2026 reported diluted EPS forecast revised to $7.18-$7.33 from prior guidance, solely due to the RBH impairment and currency effects. Adjusted diluted EPS guidance of $8.31-$8.46 implies 10.2%-12.2% growth versus 2025, or 7.5%-9.5% excluding favorable currency.

  Exhibit 99.1 verify on EDGAR →
• medium

  PM launched ZYN ULTRA in June 2026 in the U.S., offering 9mg and 11mg moist variants in a 20-pouch can at a lower price-per-pouch than the flagship dry ZYN 15-pouch format, with additional ZYN extensions planned for the rest of 2026.

  Exhibit 99.1 verify on EDGAR →